Assessment of ibrutinib plus rituximab in front-line CLL (FLAIR trial): study protocol for a phase III randomised controlled trial
DiscussionThe trial aims to provide evidence for the future first-line treatment of CLL patients by assessing whether IR is superior to FCR in terms of PFS, and whether toxicity rates are favourable.Trial registrationISRCTN01844152. Registered on 8 August 2014, EudraCT number2013-001944-76. Registered on 26 April 2013.
Source: Trials - Category: Research Source Type: clinical trials
More News: Chronic Leukemia | Chronic Lymphocytic Leukemia | Leukemia | Research | Rituxan | Study | Toxicology | Workshops